| 23392356 |
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib
Yu, C,
Albers, C,
Verbeek, M,
Duyster, J,
Leischner, H,
Illert, AL,
von Bubnoff, N,
Peschel, C
|
Leukemia |
2013 |
| 23430109 |
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD
Salerno, S,
Zhu, X,
Stewart, WK,
Lasater, EA,
Damon, LE,
Shah, NP,
Smith, CC,
Lin, KC
|
Blood |
2013 |
| 26108694 |
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
Shah, NP,
Stecula, A,
Smith, CC,
Sali, A,
Lin, K
|
Leukemia |
2015 |
| 22858906 |
Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors
Nguyen, B,
Brown, P,
Li, L,
Levis, M,
Williams, AB,
Leahy, D,
Small, D
|
Leukemia |
2013 |
| 23969938 |
Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia
Mullighan, CG,
Baker, SD,
Rubnitz, JE,
Zimmerman, EI,
Orwick, S,
Inaba, H,
Neale, GA,
Zatechka, DS,
Buaboonnam, J,
Enemark, EJ,
Shurtleff, S,
Wang, YD,
Olsen, SR
|
Clin. Cancer Res. |
2013 |
| 24227820 |
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
Levis, M,
Small, D,
Cortes, J,
Ramachandran, A,
Galanis, A,
Rajkhowa, T,
Ma, H
|
Blood |
2014 |
| 22504184 |
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Perl, AE,
Chin, CS,
Schadt, EE,
Shah, NP,
Smith, CC,
Kuriyan, J,
Hunt, JP,
Wang, Q,
Salerno, S,
Wang, S,
Levis, MJ,
Kasarskis, A,
Zarrinkar, PP,
Travers, KJ,
Damon, LE
|
Nature |
2012 |
